Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
(WorldNews Sweden)

Lund, Sweden, July 19, 2018 - Alligator Bioscience (Nasdaq Stockholm: ATORX), abiotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that the company has submitted a clinical trial authorization (CTA) application to the relevant regulatory authorities to start a phase I study of its wholly-owned bispecific drug candidate ATOR-1015. The upcoming phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with advanced solid cancer. The study will be conducted at five sites in Sweden...